Molecular Response Maintained With Intermittent Tyrosine Kinase Inhibitor Regimen in Patients With CML
Results of the ongoing OPTkIMA study comparing a fixed and a progressive TKI plan in patients with CML is discussed.
Chronic Myeloid Leukemia
American Cancer Society 2021 Statistics Report Shows Continuous Decline in Cancer Mortality Rate, Illuminates Disease-Specific Trends
The American Cancer Society’s annual report approximates the new cancer diagnoses and deaths expected in 2021 and identifies impactful patterns in oncology care.
Anti-Emetic Drug Effectively Blocks CD93 Signaling in Preclinical Evaluations, Suggesting Suitability in CML
Investigators assessed the activity of the anti-emetic agent metoclopramide in murine models.
Biosimilars in Cancer Care: Insights From 2020 and Expectations for 2021
Sean McGowan, senior director of Biosimilars at AmerisourceBergen, and Brian Ansay, senior vice president of Sales and Corporate Services at ION Solutions, review 2020 biosimilar trends in oncology and forecast what is ahead in 2021.
Iclusig Approved for Resistant or Intolerant Chronic-Phase CML
The sNDA approval is based on efficacy and safety data from the open-label phase 2 OPTIC trial and 5-year data from the phase 2 PACE trial.
AI-Based Model Made Optimal Selections of Frontline TKI Therapy in CML
Investigators report on outcomes for patients with chronic phase CML whose treatment was determined using an artificial intelligence-based model.
STAMP Inhibitor May Be a New Treatment Option in CML
Asciminib may be a new treatment option for patients with chronic myeloid leukemia in the chronic phase (CML-CP).
Discontinuation of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia
Study results suggested that the discontinuation of tyrosine kinase inhibitors for chronic myeloid leukemia may be safe, without limiting remission.
NCI-MATCH Trial Identifies Actionable Alterations in More Than One-Third of Patients With Cancer
Researchers have identified actionable alterations in nearly 38% of patients with cancer, and almost 18% of patients were assigned to treatments based on their molecular profiling results.
Targeted Therapies, Immunotherapies, Immunomodulators: A Quick Guide to Cancer Therapy Descriptions
Sometimes the distinctions between cancer treatment groups are a little blurry. Here’s a guide to their definitions and origins.
- Loading...
Loading...
Next post in General Oncology
Loading... 
Loading...